REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501 for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111 to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121 for the treatment of neurological symptoms of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV technology platform to other biotechnology companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RGNX
Previous Symbol
CUSIPN/A
Phone240-552-8181
Debt
Debt-to-Equity RatioN/A
Current Ratio20.21
Quick Ratio17.40
Price-To-Earnings
Trailing P/E Ratio-25.50
Forward P/E Ratio34.20
P/E Growth13.31
Sales & Book Value
Annual Sales$10.39 million
Price / Sales215.90
Cash FlowN/A
Price / CashN/A
Book Value$13.78 per share
Price / Book4.54
Profitability
EPS (Most Recent Fiscal Year)($2.45)
Net Income$-73,160,000.00
Net Margins44.30%
Return on Equity22.52%
Return on Assets21.31%
Miscellaneous
Employees139
Outstanding Shares35,840,000
Market Cap$2.38 billion
OptionableOptionable
Regenxbio (NASDAQ:RGNX) Frequently Asked Questions
What is Regenxbio's stock symbol?
Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."
How were Regenxbio's earnings last quarter?
Regenxbio Inc (NASDAQ:RGNX) released its earnings results on Wednesday, November, 7th. The biotechnology company reported ($0.56) EPS for the quarter, beating analysts' consensus estimates of ($0.86) by $0.30. The biotechnology company had revenue of $5.31 million for the quarter. Regenxbio had a return on equity of 22.52% and a net margin of 44.30%. View Regenxbio's Earnings History.
When is Regenxbio's next earnings date?
What price target have analysts set for RGNX?
6 equities research analysts have issued 12-month price objectives for Regenxbio's stock. Their forecasts range from $28.00 to $127.50. On average, they expect Regenxbio's share price to reach $85.0833 in the next year. This suggests a possible upside of 35.1% from the stock's current price. View Analyst Price Targets for Regenxbio.
What is the consensus analysts' recommendation for Regenxbio?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Regenxbio.
What are Wall Street analysts saying about Regenxbio stock?
Here are some recent quotes from research analysts about Regenxbio stock:
- 1. According to Zacks Investment Research, "REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. " (11/7/2018)
- 2. Raymond James analysts commented, "We are maintaining our Outperform rating and raising our target price to $76 (previously was $45) for REGENXBIO, primarily driven by our increasing confidence in the company’s pipeline products and the gene therapy space as a whole as well as the inclusion of the company’s wholly owned MPS programs into our models. With two wholly owned assets poised to deliver clinical data in late 2018, a powerful AAV technology platform with >20+ partnered programs (10 of which are in the clinic), and a cash position of $311 million (pro forma), we continue to recommend REGENXBIO shares to risk-tolerant investors." (6/25/2018)
- 3. Chardan Capital analysts commented, "We have long highlighted the importance of vector science for the progress in GT; and, we see Commissioner Gottlieb’s comments as highly supportive of our views. We again highlight REGENXBIO (Buy) (a Chardan Top Pick for 2017, and our Gene Therapy Top Pick) as the best way to play the emergence of in vivo GT, due to the company’s: (1) rights to 100+ vectors, (2) partnerships with 10 companies, (3) 25 or so internal and external product candidates, over 10 of which are in clinical development, and (4) abundance of important 2017 catalysts, which to us represent upside options." (12/11/2017)
Has Regenxbio been receiving favorable news coverage?
News articles about RGNX stock have trended negative on Monday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Regenxbio earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.
Who are some of Regenxbio's key competitors?
Some companies that are related to Regenxbio include Seattle Genetics (SGEN), Qiagen (QGEN), bluebird bio (BLUE), BIO-TECHNE (TECH), Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Autolus Therapeutics (AUTL) and Atara Biotherapeutics (ATRA).
Who are Regenxbio's key executives?
Regenxbio's management team includes the folowing people:
- Mr. Kenneth T. Mills, CEO, Pres & Director (Age 43)
- Mr. Vittal K. Vasista, Chief Financial Officer (Age 50)
- Dr. Olivier Danos, Chief Scientific Officer (Age 60)
- Mr. Curran M. Simpson, Sr. VP of Technical Operations (Age 56)
- Mr. Patrick J. Christmas II, Sr. VP & Gen. Counsel (Age 47)
Who are Regenxbio's major shareholders?
Regenxbio's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.63%), FMR LLC (3.39%), JPMorgan Chase & Co. (3.31%), Bank of New York Mellon Corp (1.11%), Botty Investors LLC (0.69%) and Prudential Financial Inc. (0.46%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for Regenxbio.
Which major investors are selling Regenxbio stock?
RGNX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Victory Capital Management Inc., Acadian Asset Management LLC, Alliancebernstein L.P., JPMorgan Chase & Co., EAM Investors LLC, Wells Fargo & Company MN and PNC Financial Services Group Inc.. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Insider Buying and Selling for Regenxbio.
Which major investors are buying Regenxbio stock?
RGNX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Russell Investments Group Ltd., Bank of New York Mellon Corp, Bank of Montreal Can, Botty Investors LLC, Chicago Equity Partners LLC, AXA and Seven Eight Capital LP. View Insider Buying and Selling for Regenxbio.
How do I buy shares of Regenxbio?
Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Regenxbio's stock price today?
One share of RGNX stock can currently be purchased for approximately $62.99.
How big of a company is Regenxbio?
Regenxbio has a market capitalization of $2.38 billion and generates $10.39 million in revenue each year. The biotechnology company earns $-73,160,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis. Regenxbio employs 139 workers across the globe.
What is Regenxbio's official website?
How can I contact Regenxbio?
Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]
MarketBeat Community Rating for Regenxbio (NASDAQ RGNX)
MarketBeat's community ratings are surveys of what our community members think about Regenxbio and other stocks. Vote "Outperform" if you believe RGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
